Image of typing on laptop

British Patient Capital commits $45m to Balderton Fund VII

Press releases

18 November 2019 – London – British Patient Capital, a subsidiary of the British Business Bank, has committed $45m into Balderton Capital Fund VII, as it closes at $400m.

The fund will focus on the Series A stage to support outstanding founders at this critical point in a start-up’s journey.

As with previous funds, Balderton will be looking to invest in leading-edge technologies, as well as strong brands with demonstrable momentum. Balderton’s existing portfolio includes Revolut, a digital bank focusing on global spending and transfers, Cambridge-based Healx, which uses AI to accelerate development of treatments for rare diseases, and Infarm, one of the world’s most advanced urban farming platforms.

Bernard Liautaud, Managing Partner at Balderton, said: “We believe Europe has the potential to build the next generation of technology giants, and we are focused on helping brilliant founders fulfil that ambition. We are seeing more and more exceptional founders raising Series A in Europe. With today’s new fund we want to build on that momentum.

“Series A is a critical point in a startup’s journey – it’s a magical moment when they are reaching product-market fit, are poised to scale and have to make decisions that can affect their growth trajectory for years to come. Our whole team is dedicated to helping our founders tackle those decisions as they embark on their journey.”

Catherine Lewis La Torre, CEO, British Patient Capital, said: “Our mission is to enable long-term investment in innovative companies across the UK, led by ambitious entrepreneurs who want to build successful world-class businesses.

“Balderton Capital invests in early-stage companies with global ambitions and is one of a few UK-based VCs with large follow-on reserves to continue to support its most promising companies into the growth stage, making it well aligned with British Patient Capital’s mandate.”

ENDS

About Balderton

Balderton Capital is a London-based venture firm focused exclusively on backing the best European-founded technology companies. In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totaling more than $3bn. Previous exited investments include Betfair (FTSE: BET), Magic Pony (Twitter), NaturalMotion (Zynga), Recorded Future (Insight Partners), Sunrise (Microsoft), Talend (NASDAQ: TLND) and Yoox Net-a-Porter (BIT: YNAP). Among Balderton’s current portfolio of over 90 companies are Aircall, Carwow, Citymapper, Contentful, Frontier Car Group, GoCardless, Hiya, The Hut Group, Kobalt Music, Labster, Nutmeg, Prodigy Finance, Revolut, SOPHiA Genetics, Vestiaire Collective, Vivino and Voi.

About British Patient Capital

British Patient Capital is the trading name of British Patient Capital Limited, a wholly-owned commercial subsidiary of the British Business Bank. Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large scale businesses.

British Patient Capital manages a £2.5bn investment fund designed to support high growth potential innovative UK businesses in accessing the long-term financing they require to scale up.

British Business Bank plc and its principal operating subsidiaries are not banking institutions and do not operate as such. A complete legal structure chart for British Business Bank plc and its subsidiaries can be found on the British Business Bank plc websiteLink opens in a new window.

British Patient Capital

Gill Corish

Senior Communications Manager
Phone: 020 377 21312 or 07889 786854
Email: gill.corish@british-business-bank.co.uk

Mary Whenman

Communications Director
Phone: 0203 905 1495 or 07799 860 980
Email: mary.whenman@british-business-bank.co.uk

The British Patient Capital team at MHP Communications

Phone: 020 3128 8589
Email: bbb@mhpc.com